Because most of the lung cancer patients are males and DAB2IP deficient was also founded in lung cancer [15], it is likely that the genetic variation in DAB2IP gene may contribute to increase the risk of lung cancer as it did in prostate cancer. This evidence concerns the gene DAB2IP and lung carcinoma.